Cagrilintide 5mg Dosage & Mixing Guide

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog (an amylin/calcitonin receptor agonist) developed by Novo Nordisk for weight-management research. It was engineered to mimic the effects of the naturally occurring hormone amylin while providing an extended duration of action.

The peptide works by activating amylin receptors, which promotes satiety, slows gastric emptying, and reduces food intake. These effects complement GLP-1 signaling pathways, which is why cagrilintide is studied in combination with semaglutide as “CagriSema.”

Cagrilintide has an extended half-life compared to native amylin, allowing for once-weekly administration in research protocols.

Quick Reference

Reconstitution Guide

Materials Needed

• Cagrilintide 5mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the Cagrilintide vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.

3. Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle into the Cagrilintide vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.

5. Allow to dissolve — Cagrilintide may take 5-10 minutes to fully dissolve. Gently swirl occasionally — never shake vigorously.

6. Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.

7. Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.

Dosage Protocol

Concentration Calculations

With 5mg peptide in 2mL BAC water:

• Concentration: 2.5mg/mL = 2500mcg/mL
• Per unit (U-100 syringe): 25mcg per unit

Common Dose Calculations

Suggested Titration Protocol

Cagrilintide research protocols typically employ gradual dose escalation to assess tolerance:

Important Notes:

• Each dose level should be maintained for at least 4 weeks before escalation
• Not all research protocols require reaching maximum dose
• Dose escalation should be based on research objectives and tolerance

Injection Guide

Subcutaneous Administration

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin (abdomen, thigh, or upper arm)
3. Insert needle at 90° angle for most body types
4. Inject slowly and steadily
5. Wait 5-10 seconds before withdrawing needle
6. Apply light pressure if needed — do not rub

Site Rotation

Rotate between these areas weekly:

• Abdomen (2+ inches from navel) — most common
• Outer thigh (front/outer area)
• Back of upper arm

Consistency tip: Administer on the same day each week to maintain steady levels.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C (36-46°F) — standard refrigerator
• Duration: 4-6 weeks
• Conditions: Keep away from light, never freeze reconstituted solution

Important Storage Notes

• Cagrilintide is sensitive to temperature — minimize time outside refrigeration
• Do not use if solution becomes cloudy, discolored, or contains particles
• Keep track of reconstitution date and discard after 6 weeks maximum

Research Considerations

Mechanism of Action

Cagrilintide’s research applications stem from its amylin receptor agonism:

• Satiety signaling: Activation of amylin receptors to promote fullness
• CNS effects: Appetite regulation and reduced food intake
• GI effects: Slowed gastric emptying
• Combination potential: Complements GLP-1 pathways (studied with semaglutide as CagriSema)

Key Research Findings

Clinical trials have demonstrated:

• Significant effects on body weight in metabolic research
• Once-weekly dosing supported by an extended half-life
• Additive effects when combined with GLP-1 receptor agonists

Safety & Handling

General Precautions

• Use sterile technique for all preparations
• Never reuse needles or syringes
• Dispose of sharps properly in designated containers
• Store away from children and unauthorized persons

Research Considerations

• Cagrilintide is for research purposes only
• Cagrilintide is not an approved medicine
• Research-grade peptides are not equivalent to pharmaceutical preparations
• Follow institutional guidelines for peptide research

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Lau DCW, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet. 2021.
2. Enebo LB, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management.” The Lancet. 2021.

Last updated: July 04, 2026

Disclaimer: This information is for educational and research purposes only. Cagrilintide as a research peptide is not intended for human consumption. Cagrilintide is not an approved medicine. Always follow applicable laws and institutional guidelines.